Enlaza Therapeutics
San Diego, US · 5 known investors
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
Founders & leadership
SD
Sergio DuronCo-Founder & Chief Executive Officer
SM
Sanford MadiganCo-Founder, President & Chief Business Officer
AH
Analeah HeidtChief Scientific Officer